- Home
- AGL vs ORIC Comparison
AGL vs ORIC Comparison
Compare AGL & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- ORIC
- Stock Information
- Founded
- AGL 2016
- ORIC 2014
- Country
- AGL United States
- ORIC United States
- Employees
- AGL N/A
- ORIC N/A
- Industry
- AGL Managed Health Care
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- ORIC Health Care
- Exchange
- AGL Nasdaq
- ORIC Nasdaq
- Market Cap
- AGL 952.1M
- ORIC 974.1M
- IPO Year
- AGL 2021
- ORIC 2020
- Fundamental
- Price
- AGL $1.10
- ORIC $10.86
- Analyst Decision
- AGL Hold
- ORIC Strong Buy
- Analyst Count
- AGL 20
- ORIC 10
- Target Price
- AGL $3.03
- ORIC $17.33
- AVG Volume (30 Days)
- AGL 7.3M
- ORIC 864.1K
- Earning Date
- AGL 11-06-2025
- ORIC 11-11-2025
- Dividend Yield
- AGL N/A
- ORIC N/A
- EPS Growth
- AGL N/A
- ORIC N/A
- EPS
- AGL N/A
- ORIC N/A
- Revenue
- AGL $5,901,182,000.00
- ORIC N/A
- Revenue This Year
- AGL N/A
- ORIC N/A
- Revenue Next Year
- AGL $7.04
- ORIC N/A
- P/E Ratio
- AGL N/A
- ORIC N/A
- Revenue Growth
- AGL 11.76
- ORIC N/A
- 52 Week Low
- AGL $0.71
- ORIC $3.90
- 52 Week High
- AGL $6.08
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- AGL 37.45
- ORIC 58.46
- Support Level
- AGL $1.03
- ORIC $10.36
- Resistance Level
- AGL $1.29
- ORIC $11.20
- Average True Range (ATR)
- AGL 0.10
- ORIC 0.46
- MACD
- AGL 0.01
- ORIC 0.09
- Stochastic Oscillator
- AGL 17.60
- ORIC 76.90
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.